International Journal of Hematology

, Volume 107, Issue 4, pp 428–435 | Cite as

Vwf K1362A resulted in failure of protein synthesis in mice

  • Naomi Sanda
  • Nobuaki Suzuki
  • Atsuo Suzuki
  • Takeshi Kanematsu
  • Mayuko Kishimoto
  • Hidetoshi Hasuwa
  • Akira Takagi
  • Tetsuhito Kojima
  • Tadashi Matsushita
  • Shigeo Nakamura
Original Article
  • 98 Downloads

Abstract

Von Willebrand factor (VWF) is synthesized in megakaryocytes and endothelial cells (ECs) and has two main roles: to carry and protect coagulation factor VIII (FVIII) from degradation by forming VWF–FVIII complex; and to mediate platelet adhesion and aggregation at sites of vascular injury. Previous research using the HEK293 cell line revealed that the VWF K1362 mutation interacted directly with platelet glycoprotein Ib (GPIb). Vwf K1362A knock-in (KI) mice were therefore generated to verify the in vivo function of residue 1362 in binding to platelet GPIb. The Cre-loxP system was employed to introduce the Vwf K1362A mutation systemically in mice. In blood coagulation analysis, the VWF antigen (VWF:Ag) of Lys1362Ala KI homozygous (homo) mice was below the sensitivity of detection by enzyme-linked immunosorbent assay. FVIII activities (FVIII:C) were 47.9 ± 0.3 and 3.3 ± 0.3% (K1362A heterozygous (hetero) and K1362A KI homo mice, respectively) compared to wild-type mice. Immunohistochemical staining analysis revealed that VWF protein did not exist in ECs of K1362A KI homo mice. These results indicated that VWF protein synthesis of K1362A was impaired after transcription in mice. K1362 seems to represent a very important position not only for VWF function, but also for VWF synthesis in mice.

Keywords

Von Willebrand factor Mouse model Genetic mutation 

Notes

Acknowledgements

We would like to thank NPO Biotechnology Research and Development for technical assistance. We wish to thank the staff of the Division of Experimental Animals at Nagoya University Graduate School of Medicine for their technical support. We are also grateful to Kimiko Sannodo for obtaining blood from mice and PCR typing.

Compliance with ethical standards

Conflict of interest

This research was supported by JSPS KAKENHI Grant Number JP 22591059 and Novartis Research Grants.

References

  1. 1.
    Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem. 1986;261:12579–85.PubMedGoogle Scholar
  2. 2.
    Vicente V, Houghten RA, Ruggeri ZM. Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J Biol Chem. 1990;265:274–80.PubMedGoogle Scholar
  3. 3.
    Murata M, Ware J, Ruggeri ZM. Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ib alpha demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol Chem. 1991;266:15474–80.PubMedGoogle Scholar
  4. 4.
    Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem. 1991;266:8149–55.PubMedGoogle Scholar
  5. 5.
    Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex. Biochemistry. 1989;28:8317–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Fukuda K, Doggett T, Laurenzi IJ, Liddington RC, Diacovo TG. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol. 2005;12:152–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem. 1995;270:13406–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Matsushita T, Meyer D, Sadler JE. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem. 2000;275:11044–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Inoue N, Ikawa M, Isotani A, Okabe M. The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs. Nature. 2005;434:234–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science (New York, NY). 2002;297:1176–9.CrossRefGoogle Scholar
  11. 11.
    Pendu R, Christophe OD, Denis CV. Mouse models of von Willebrand disease. J Thromb Haemost. 2009;7(Suppl 1):61–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen J, Zhou H, Diacovo A, Zheng XL, Emsley J, Diacovo TG. Exploiting the kinetic interplay between GPIbalpha-VWF binding interfaces to regulate hemostasis and thrombosis. Blood. 2014;124:3799–807.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998;273:10396–401.CrossRefPubMedGoogle Scholar
  14. 14.
    Hommais A, Stépanian A, Fressinaud E, Mazurier C, Meyer D, Girma JP, et al. Mutations C1157F and C1234 W of von Willebrand factor cause intracellular retention with defective multimerization and secretion. J Thromb Hemost. 2006;4:148–57.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Naomi Sanda
    • 1
    • 2
  • Nobuaki Suzuki
    • 3
  • Atsuo Suzuki
    • 1
  • Takeshi Kanematsu
    • 4
  • Mayuko Kishimoto
    • 4
  • Hidetoshi Hasuwa
    • 5
    • 6
  • Akira Takagi
    • 7
  • Tetsuhito Kojima
    • 7
  • Tadashi Matsushita
    • 3
    • 4
  • Shigeo Nakamura
    • 2
  1. 1.Department of Medical TechniqueNagoya University HospitalNagoyaJapan
  2. 2.Department of Pathology and Clinical LaboratoriesNagoya University Graduate School of MedicineNagoyaJapan
  3. 3.Department of Transfusion MedicineNagoya University HospitalNagoyaJapan
  4. 4.Department of Clinical LaboratoryNagoya University HospitalNagoyaJapan
  5. 5.Department of Experimental Genome ResearchResearch Institute for Microbial DiseasesOsakaJapan
  6. 6.Department of Molecular BiologyKeio University School of MedicineTokyoJapan
  7. 7.Department of Pathophysiological Laboratory SciencesNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations